As clinical trials create large amounts of data, and researchers seize the opportunity to use de-identified data as a means to develop and discovery, managing the information has become more and more complex.
Datathon participants identify five repurposable drug candidates, applying AI to identify genes of interest and support target identification – a task that previously would have taken years, says industry expert.
With the recent marriage between technology and science aimed at innovating aspects of clinical trials panels composed of experts from fields outside of pharma could prove to be impactful.
Artificial intelligence advances threaten data privacy, according to a new study, which found it is possible to re-identify individuals using their physical activity data.
Medidata is working with Cognizant to develop a set of services that will provide pharma, biotech, CROs and others with the capabilities to “digitally transform” their research and commercialization.
MedPharm expands its US Center of Excellence in Durham, North Carolina, in response to increasing demand for its topical and transdermal formulation development, and performance testing services.
The industry group recently announced its first technology standard, which addresses operational data exchange in an aim to improve information sharing between sponsors and CROs.
Awareness around the potential opportunities created by artificial intelligence has never been higher, but pharma’s biggest challenge in 2019 will be adopting and scaling the right technology to improve patient outcomes, says an industry executive.
TrialScope this year awarded several companies for their clinical trial data transparency efforts as the industry makes strides to engage patients and the larger health care community.
The Pistoia Alliance hopes to facilitate “seamless data integration” between various industry stakeholders, including life sciences companies and CROs, via an open and freely available data format.
ICH E6 R2 sparked a paradigm shift, though 2019 will see the clinical trials industry transition from a risk-based monitoring approach to risk-based quality management.
The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts.
Rather than limit health care data collection, the industry should focus on ensuring those data sets are used ‘in the most appropriate way,’ according to Health iQ chief commercial officer.
Certara is using Hedera’s next-generation distributed ledger technology to help the pharmaceutical industry and other stakeholders to ‘capitalize on the myriad of seemingly insignificant activities.’
The FDA recently released a draft guidance address penalties for those not disclosing clinical trial results, as patients, the scientific community, and other stakeholders call for increased transparency.
The recent FDA guidance ties penalties for not disclosing clinical trial results to formal inspections – falling short of the public expectation that such data should be readily available, says industry expert.
The drug development consultancy Certara this week has purchased a pharmacometrics modeling workbench and released a cloud-based platform to allow therapeutic decision-making apps to be delivered at the point of care.
Cytel examines the gap between controlled experiment and real-world data at a time when the industry is collecting more data from more sources than ever before.
Hu-manity.co is taking on the human data marketplace with its mission to establish a 31st Human Right: Legal ownership of human data as property – a shift that could help improve clinical research and increase transparency, to begin.
To improve clinical trial design, site selection, and patient enrollment, the real-world data solutions firm Clinerion is partnering with Patient iP, a health data and analytics company.
Tjoapack and Veratrak partnered to establish the use of blockchain technology across the pharmaceutical industry for the first time in a GxP environment.
Harvard Medical School and Brigham Women’s Hospital have selected the Aetion Evidence Platform to further support the REPEAT program and the demand for RWE.
TransCelerate and BioCelerate have launched a new data sharing platform to connect preclinical and clinical information to help better inform clinical trials.
CTTI’s latest recommendations will help researchers deploy mobile technologies in clinical trials and “pave the way for improving how we develop medicines,” says Pfizer exec.
Pan-American countries should adopt EMA-style regulations to increase clinical trial transparency and streamline research, according to a recent report.
The industry needs “to strike a balance” between science and feasible execution as increasingly complex clinical trial protocols are impeding efficiency and driving up costs, says industry expert.
Japan-based ONO Pharmaceutical will use CluePoints’ centralized statistical monitoring platform to lead its RBM strategy over the next four years following a successful pilot study in 2017.
GlaxoSmithKline has selected TrialScope to facilitate clinical trial disclosure and transparency – as the benefits of patient centricity are paramount, and the risks of poor compliance magnified, says VP.
Innovations in drug development positively affect clinical trial timelines, market launch likelihood, and patient access – though adoption remains low, says report.
Akebia Therapeutics has signed a master services agreement with CRO Quintiles in connection with its planned Phase III studies for Akebia’s lead product candidate for the treatment of anemia secondary to chronic kidney disease in non-dialysis patients.
Ingenuity Systems, the California, US-based life sciences software developer has announced a research collaboration with US contract research organisation (CRO), Covance.
AniClin Preclinical Services has formed a strategic alliance with Taylor Technology, a subsidiary of PharmaNet, to offer clients complete pharmacokinetic (PK) studies in fewer than five days.
PPD is targeting growing demand for contract data analysis with a new biostatistics infrastructure that, it says, offers improved security and reporting.
The EMEA is fast tracking the review of data on H1N1 pandemic vaccines to ensure it has checked submissions before the northern hemisphere flu season, which starts in September.